The Journal of pediatrics · 2025
The Natural History of Congenital Hepatic Hemangiomas.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ostertag-Hill Claire A, Fevurly R Dawn, Kulungowski Ann M, Christison-Lagay Emily R, McGuire Anna M, Rialon Kristy L, Duggan Eileen M, Murillo Rudy, Zurakowski David, Staffa Steven J, Alomari Ahmad I, Kozakewich Harry P W, Al-Ibraheemi Alyaa, Fishman Steven J, Dickie Belinda H
Аннотация
OBJECTIVE: To characterize the clinical presentation, radiologic and histologic findings, and management options for congenital hepatic hemangioma (HH) with a focus on describing its natural history and rate of involution.
STUDY DESIGN: Retrospective review of patients in our HH registry with a congenital HH born between 2004 and 2022 was performed. HH volumes were calculated using the formula for an ellipsoid. Multiple analyses of HH volume change were performed using nonlinear regression with generalized estimating equations, Kaplan-Meier curves, and logrank test.
RESULTS: We identified 96 infants with a congenital HH. Of these, 32% were diagnosed prenatally, 23% developed heart failure, and 23% developed respiratory failure. On average, patients demonstrated 43% residual HH volume at 12 months (95% confidence interval: 27%-60%) and 16% residual volume at 24 months (95% confidence interval: 0%-35%). No difference in time to 50% HH volume reduction between patients with and without medical therapy was observed (P = .894).
CONCLUSION: Congenital HH represents the hepatic counterpart of the cutaneous congenital hemangioma and is clinically, histologically, and radiographically distinct from infantile HH. Most lesions reach >80% involution by 24 months of age with no differences in time to involution observed with medical therapy. A clear understanding of the clinical behavior and evolution of congenital HH is critical to early recognition of associated morbidity and prompt review of an incorrect diagnosis.
STUDY DESIGN: Retrospective review of patients in our HH registry with a congenital HH born between 2004 and 2022 was performed. HH volumes were calculated using the formula for an ellipsoid. Multiple analyses of HH volume change were performed using nonlinear regression with generalized estimating equations, Kaplan-Meier curves, and logrank test.
RESULTS: We identified 96 infants with a congenital HH. Of these, 32% were diagnosed prenatally, 23% developed heart failure, and 23% developed respiratory failure. On average, patients demonstrated 43% residual HH volume at 12 months (95% confidence interval: 27%-60%) and 16% residual volume at 24 months (95% confidence interval: 0%-35%). No difference in time to 50% HH volume reduction between patients with and without medical therapy was observed (P = .894).
CONCLUSION: Congenital HH represents the hepatic counterpart of the cutaneous congenital hemangioma and is clinically, histologically, and radiographically distinct from infantile HH. Most lesions reach >80% involution by 24 months of age with no differences in time to involution observed with medical therapy. A clear understanding of the clinical behavior and evolution of congenital HH is critical to early recognition of associated morbidity and prompt review of an incorrect diagnosis.